Your browser doesn't support javascript.
loading
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1.
Jenson, Justin M; Ryan, Jeremy A; Grant, Robert A; Letai, Anthony; Keating, Amy E.
Affiliation
  • Jenson JM; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States.
  • Ryan JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.
  • Grant RA; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States.
  • Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.
  • Keating AE; Department of Biology, Massachusetts Institute of Technology, Cambridge, United States.
Elife ; 62017 06 08.
Article in En | MEDLINE | ID: mdl-28594323
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Proto-Oncogene Proteins / Proto-Oncogene Proteins c-bcl-2 / Apoptosis Regulatory Proteins / Mutation Type of study: Prognostic_studies Language: En Journal: Elife Year: 2017 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptide Fragments / Proto-Oncogene Proteins / Proto-Oncogene Proteins c-bcl-2 / Apoptosis Regulatory Proteins / Mutation Type of study: Prognostic_studies Language: En Journal: Elife Year: 2017 Document type: Article Affiliation country: Country of publication: